Shares of Emergent Biosolutions Has Risen Above Previous 52-Week High
Emergent Biosolutions (NYSE:EBS) traded at a new 52-week high today of $42.85. Approximately 81,000 shares have changed hands today, as compared to an average 30-day volume of 408,000 shares.
Over the past year, Emergent Biosolutions has traded in a range of $27.68 to $42.85 and is now at $42.85, 55% above that low. Over the last five market days, the 200-day moving average (MA) has gone up 0.3% while the 50-day MA has advanced 0.3%.
Emergent Biosolutions (NYSE:EBS) defies analysts with a current price ($42.85) 0.8% above its average consensus price target of $42.50. The stock should discover initial support at its 50-day moving average (MA) of $36.67 and subsequent support at its 200-day MA of $35.01.
Emergent Biosolutions, Inc. develops and produces immunobiotics, pharmaceutical products that assist the body's immune system to prevent or treat disease. The Company produces a vaccine for anthrax.
SmarTrend recommended that subscribers consider buying shares of Emergent Biosolutions on March 30th, 2016 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $35.86. Since that recommendation, shares of Emergent Biosolutions have risen 17.3%. We continue to monitor EBS for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.
Keywords: 52 week high/lows emergent biosolutions